Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
T. Hemmi, A. Ainai, T. Hashiguchi, M. Tobiume, T. Kanno, N. Iwata-Yoshikawa, S. Iida, Y. Sato, S. Miyamoto, A. Ueno, K. Sano, S. Saito, N. Shiwa-Sudo, N. Nagata, K. Tamura, , T. Suzuki
This study shows that an intranasal vaccine with CpG ODN2006 induces secretory IgA antibodies against SARS-CoV-2 variants and reduces lung eosinophilic immunopathology compared to subcutaneous vaccination.
bioRxiv · May 24, 2022Microbiology